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ABSTRACT 
ALK positive anaplastic large cell lymphoma is characterized by 2p23/ALK aberrations, including the 
classic t(2;5)(p23;q35)/NPM1-ALK rearrangement present in ~80% of cases and several variant 
t(2p23/ALK) occurring in the remaining cases. The ALK fusion partners play a key role in the 
constitutive activation of the chimeric protein and its subcellular localization. Using various molecular 
technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell 
lymphoma cases with cytoplasmic-only ALK expression. The identified partner genes included EEF1G 
(one case), RNF213/ALO17 (one case), ATIC (four cases) and TPM3 (two cases). Notably, all cases 
showed copy number gain of the rearranged ALK gene, which is never observed in NPM1-ALK-
positive lymphomas. We hypothesized that this could be due to lower expression levels and/or lower 
oncogenic potential of the variant ALK fusions. Indeed, all partner genes, except EEF1G, showed 
lower expression in normal and malignant T cells, in comparison with NPM1. In addition, we 
investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by 
CRISPR/Cas9 genome editing in Ba/F3 cells. We found that Npm1-Alk has a stronger transformation 
potential than Atic-Alk, and we observed a subclonal gain of Atic-Alk after a longer culture period, 
which was not observed for Npm1-Alk. Taken together, our data illustrate that lymphomas driven by 
the variant ATIC-ALK fusion (and likely by RNF213-ALK, and TPM3-ALK), but not the classic NPM1-
ALK, require an increased dosage of the ALK hybrid gene to compensate for the relatively low and 
insufficient expression and signaling properties of the chimeric gene. 
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Introduction 
Anaplastic large cell lymphoma (ALCL) expressing the anaplastic lymphoma kinase (ALK) (ALK+ 
ALCL) is a rare but well-defined subtype of peripheral T-cell lymphoma (PTCL).1 It accounts for 
approximately 3% of all non-Hodgkin lymphomas (NHL) in adults, for 10-15% of pediatric lymphomas 
and 60-80% of all ALCLs. ALK+ ALCL is hallmarked by various 2p23/ALK chromosomal 
rearrangements leading to an aberrant expression and constitutive activation of the ALK tyrosine 
kinase. The most prevalent lesion occurring in more than 80% of ALK+ ALCL is t(2;5)(p23;q35) 
involving ALK and NPM1 (nucleophosmin) genes, respectively.2 The translocation generates a 
chimeric protein comprising the N-terminus oligomerization domain of NPM1 and the C-terminus of 
ALK, including its intracellular tyrosine kinase domain.2 The fusion acts as an oncogene and its 
transforming potential was proven in a number of in vitro and in vivo studies.3-5 The remaining ALK+ 
ALCL cases harbor variant 2p23/ALK rearrangements affecting at least nine partners genes: TPM3 
(1q21.3; previously assigned to 1q256), ATIC (2q35), TFG (3q12.2), TRAF1 (9q33.2), CLTC (17q23.1), 
ALO17/RNF213 (17q25.3), TPM4 (19p13.12), MYH9 (22q12.3) and MSN (Xq12).7 The partners play a 
key role in the constitutive activation of the chimeric protein by mediating its oligomerization and 
determine subcellular localization of ALK fusion (cytoplasmic and nuclear, in NPM1-ALK positive 
cases, and cytoplasmic-only or membranous, in variant fusions)8,9. In addition, they impact a range of 
biological activities of ALK chimeras, including proliferation, transformation and metastatic 
capacities.10,11 Comparative analysis of biological properties of ALK oncoproteins, however, is 
hampered by the relative low frequency of particular variant ALK fusions.  
Interestingly, ALK rearrangements have been also detected in large B-cell lymphoma and various 
tumors of mesenchymal and epithelial origin, including inflammatory myofibroblastic tumors, lung 
cancer, esophageal squamous cell carcinoma and others.7 Notably, the same ALK fusions, such as 
TPM3-ALK, TPM4-ALK, TFG-ALK, SEC31A-ALK, ATIC-ALK, CLTC-ALK and EML4-ALK occur in 
ALK+ malignancies of different cell of origin highlighting the crucial role of ALK in tumorigenesis.7,12 
These findings prompted development of new therapeutic strategies in ALK+ tumors. Particularly 
important is the recent discovery of specific ALK tyrosine inhibitors.13,14 One of them, crizotinib, has 
proven to have clinical efficacy in treatment of ALK+ non-small cell lung cancer and ALCL.15,16 
Here, we report molecular characterization of ALK fusions in eight ALK+ ALCL cases exhibiting a 
cytoplasmic-only ALK staining pattern recently diagnosed in our institution. Intriguingly, all cases 
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analyzed by fluorescence in situ hybridization (FISH) at time of diagnosis revealed copy number gain 
of the rearranged ALK gene.  
 
Methods 
Case selection 
Eight cases of ALK+ ALCL with a cytoplasmic-only expression of ALK and available bioarchived 
material were selected from the database of the Center for Human Genetics and Department of 
Pathology, Universisty Hospital of the KU Leuven, Belgium. Morphology, immunophenotype and 
clinical records of the reported cases were reviewed. The institutional review board “Commissie 
Medische Ethiek” of the University Hospital approved this retrospective study and they renounced the 
need for written informed consent from the participants (S56799, ML10896: 12/08/2014).  
 
Cytogenetics and FISH  
Conventional G-banding chromosomal analysis and FISH analysis followed routine protocols. The 
probes applied on patient material and Ba/F3 cell lines are listed Supplemental Table 1. Non-
commercial probes were directly labeled with SpectrumOrange- and SpectrumGreen-d-UTP (Abbot 
Molecular, Ottignies, Belgium) by random prime labeling. FISH images were acquired with a 
fluorescence microscope equipped with an Axiophot 2 camera (Carl Zeiss Microscopy, Jena, 
Germany) and a MetaSystems Isis imaging system (MetaSystems, Altussheim, Germany). 
 
Array-based genomic hybridization (aCGH) 
Total genomic DNA was isolated from frozen lymphoma samples using standard procedures. High-
resolution aCGH was performed using the Affymetrix Cytoscan HD arrays (www.affymetrix.com) and 
followed the manufacturer protocols. Downstream data analysis of copy number alterations was 
conducted using the software ArrayStudio, version 6.2 (www.omicsoft.com).  
 
Cell culture and growth curves 
Ba/F3 cells constitutively expressing Cas9 (Ba/F3 Cas9) were generated using a retroviral 
expression vector containing a Cas9 expression cassette (Supplemental Figure 1). Ba/F3 Cas9 cells 
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were cultured with IL3 in RPMI medium + 10% FBS before and after electroporation. For growth 
curves, viability and proliferation were measured on a Guava flow cytometer (Merck Millipore, 
Darmstadt, Germany) for several consecutive days.   
 
Quantitative RT-PCR (QRT-PCR) 
QRT-PCR with the GoTaq qPCR Master Mix (Promega, Madison, Wisconsin) was used to analyze 
relative mRNA expression of two Alk partner genes (Npm1 and Atic) in Ba/F3 Cas9 cells. Mouse Hprt1 
and Rpl4 were used as an internal control. Primers are listed in Supplemental Table 2. All samples 
were run in triplicate and data were analyzed with the comparative Ct (∆∆Ct) method.  
 
CRISPR/Cas genome editing 
gRNAs were designed using the CRISPR design tool of the Zhang lab (crispr/mit.edu) 
(Supplementary Table 3). gRNAs were cloned into an expression plasmid (pX321, derived from 
pX330, Zhang lab; Supplemental Figure 2). Electroporations of Ba/F3 Cas9 cells were carried out 
using a Gene Pulser Xcell electroporation system (Biorad, Hercules, California). After electroporation, 
cells were kept in RPMI medium + 10% FBS + IL3 for 3 days before IL3 depletion was carried out. 
 
Other applied techniques, including the 5’ Rapid Amplification of cDNA Ends Polymerase-Chain-
Reaction (RACE-PCR), Low Coverage Full Genome Sequencing (LCFGS), Targeted Locus 
Amplification (TLA) and Nested Reverse-Transcription Polymerase-Chain-Reaction (RT-PCR) are 
briefly described in Supplemental Methods.  
 
Results 
Clinical and pathological features 
Relevant clinical and pathological features of the reported cases of ALK+ ALCL are shown in Table 
1. There were two children (a 5 year-old boy and a 13 year-old girl) and six adults (two female and 
four males) in age ranging from 49 to 78 years (mean 64.8 year). All patients presented with lymph 
node involvement and one displayed additional skin lesions [stages I (cases 3 and 4), II (cases 5 and 
8), III (cases 2 and 7) and IV (cases 1 and 6)]. Five adult patients (cases 2-6) were treated with 
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chemotherapy (CHOP), reached complete remission (CR) and are alive. The sixth adult patient (case 
7) initially diagnosed as classical Hodgkin lymphoma, was treated with ABVD and radiotherapy, and 
also reached CR. He relapsed very recently (after 165 months) and died due to disease-related 
complications after the 3rd course of CHOP. Two other patients also experienced more aggressive 
course: one (case 2) achieved a second CR after DHAP and the first pediatric patient (case 1) initially 
treated according to the ALCL99 protocol, experienced three relapses. He achieved CR after 
treatment with crizotinib and allogenic stem cell transplantation but died 72 months after diagnosis due 
to severe GVHD and respiratory failure. The second pediatric patient (case 8) got 6 cycles of 
polychemotherapy (ALCL99) and remains in CR.  
 Histopathology showed an anaplastic lymphoid cell proliferation with characteristic hallmark and 
doughnut cells in all cases. The immunophenotype of the individual tumors is shown in Table 1 and 
illustrated in Supplemental Figure 3. All cases were CD30 positive, expressed a CD4+ or null cell 
phenotype in conjunction with variable cytotoxic markers, and overexpressed ALK1 in a strictly 
cytoplasmic pattern. The stromal infiltrate was prominent in all cases with a variable amount of 
histiocytes and/or neutrophils. 
 
Cytogenetic and molecular studies   
Case 1. Cytogenetic analysis showed a complex karyotype with del(2)(p23) (Table 2). FISH with 
LSI ALK demonstrated a break apart pattern with the green (5’ALK) signal on del(2)(p23) and two red 
(3’ALK) signals on a marker chromosome of postulated chromosome 11 origin (Figure 1A). Whole 
chromosome painting proved that der(11) indeed harbors the duplicated fragment of chromosome 2 
inserted at 11q. The t(2p23/ALK) rearrangement was further investigated using the 5’ RACE PCR 
approach. The analysis identified an in-frame fusion transcript in which exon 8 of EEF1G, the gene 
located at 11q12.3, was fused to exon 20 of ALK (Figure 1B). More precisely, the fusion joined 
nucleotide 1161 of EEF1G (NCBI ref NM-001404), corresponding to an intronic region between exons 
8 and 9, with nucleotide 4226 of ALK (NM-004304) situated in exon 20. The EEF1G-ALK fusion was 
subsequently confirmed by Sanger sequencing of the fragment obtained by nested RT-PCR (Figure 
1B) and by FISH using probes for 5’EEF1G and 3’ALK (not shown). Array CGH analysis demonstrated 
the 3’ALK-involving gain of 2p23.2p25.3 and the EEF1G-affecting gain of 11q11q13.4 (Figure 1C-D). 
In addition, gain of five other regions, loss of three large regions, including 9p21.3p24.3/CDKN2A/B, 
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and three microdeletions were detected (Figure 1C; Table 1). Interestingly, the focal deletion at 
8q24.21 covered of ~280 kbp sequences flanking the centromeric border of MYC. The loss was 
confirmed by FISH with LSI MYC: one of two apparently normal looking chromosomes 8 [der(8)] 
revealed a significantly diminished red signal (Figure 1A).  
 
Case 2. Cytogenetic analysis was unsuccessful. Interphase FISH with LSI ALK showed a break 
apart pattern associated with gain of up to seven red (3’ALK) signals (Figure 2A). The FISH pattern 
suggested a diploid and tetraploid status of abnormal cells. The ALK rearrangement was further 
investigated using LCFGS. The analysis identified the RNF213-ALK fusion (supported by at least 8 
read pairs) where the exon 8 of RNF213 is fused to exon 20 of ALK, resulting in an in-frame fusion 
transcript equal to the previously described cases (Figure 2B).6,17,18 The fusion and its gain were 
confirmed by FISH (Figure 2A). The performed aCGH analysis demonstrated the ALK- and RNF213-
associated gain of 2p23.2p25.3 and 17q23.3q25.3, respectively (Figure 2C-D). In addition, aCGH 
detected gain of six other regions and loss of three regions, all listed in Table 2. Notably, breakpoints 
of the amplified 4p12p16 and 5q33.3q35.3 regions affected the RNF212/4p16 and ITK/5q33.3 genes, 
respectively. FISH with the respective break apart (BA) probes (Supplemental Table 1) confirmed the 
unbalanced rearrangement and partial gain of both genes. Further FISH with the probes for 5’RNF212 
and 3’ITK showed multiple, but not colocalized signals, precluding the RNF212-ITK hybrid gene (data 
not shown). Unfortunately, LCFGS has not identified any fusion of RNF212 and ITK.  
 
Cases 3-6. The cases were not subjected to cytogenetic analysis. FISH with LSI ALK applied on 
formalin fixed paraffine embeded (FFPE) material confirmed ALK rearrangement and displayed 
presence of 3-7 red (3’ALK) signals in all cases (Table 2, Figure 3A). Although a number of fused (F), 
red (R) and green (G) signals in analyzed cells varied, all cases showed a clear predominance of the 
red signals and variations of the 1F1G3R pattern. As a similar pattern was observed in ATIC-ALK-
positive lymphoma19, we examined at first the status of this gene. FISH with the ATIC BA assay 
revealed a break apart pattern and presence of extra 5’ATIC signals in all four cases (Figure 3B). 
Subsequent FISH with the 5’ATIC and 3’ALK probes demonstrated 3-5 fused signals per cell 
confirming the ATIC-ALK rearrangement and gain of the chimeric gene in all four cases (Figure 3C).   
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Case 7. The biopsy taken at time of relapse (2016) showed a complex diploid karyotype with a 
presumed ins(1;?)(q21;?) and ider(1)(q10) containing a duplicated 1q arm of ins(1;?)(q21;?) and 
del(2)(p23) (Table 2, Figure 3D). Interphase FISH with LSI ALK revealed the 1F1G3R pattern (Figure 
3E), like in ATIC-ALK positive cases. Considering that the 1q21 breakpoint merges with localization of 
TPM3, the known ALK partner,6 a possible involvement of this gene was investigated by FISH with the 
designed TPM3 BA assay (Supplemental Table 1). Neoplastic cells revealed the 1F3(RsepG) pattern 
postulating rearrangement of TPM3 due to ins(1;2)(q21.3;p23p25) (Figure 3F). The TPM3-ALK fusion 
was subsequently confirmed by FISH using the 5’TPM3/3’ALK probes. In the next step, we revised the 
diagnostic sample (the case was initially misdiagnosed as classical Hodgkin lymphoma), in which 
cytogenetic analysis identified rare hypertetraploid cells with i(1)(q10) and del(2)(p23) (Table 2). FISH 
with LSI ALK (Figure 3G), TPM3 BA (Figure 3H) and the 5’TPM3/3’ALK probes (Figure 3I) 
demonstrated presence of the TPM3-ALK rearrangement and copy number gain of the ALK fusion 
already at time of diagnosis (2002). 
 
Case 8. Cytogenetic analysis identified only one abnormal (near tetraploid) metaphase cell 
harboring five copies of chromosome 2 (Table 2). LSI ALK applied on this chromosome spread 
hybridized with all chromosomes 2: one showed a fused signal and other four were marked by red 
signals (Fig 3J). The abnormal FISH pattern (1-2F4R) was detected in 11% of interphase cells. Loss 
of the 5’ALK sequences suggested a focal interstitial del(2)(p23p23) leading to a novel fusion of ALK 
with a gene located at the centromeric breakpoint of the deletion. To identify a potential partner gene, 
we used TLA approach. Unexpectedly, the analysis identified the TPM3-ALK fusion with the 
breakpoints at the intron 7 of TPM3 and the intron 19 of ALK (Supplemental Figure 4). FISH confirmed 
the TPM3 rearrangement, which was associated with loss of the 3’TPM3 sequences, and showed that 
four out of five chromosomes 2 harbor one copy of TPM3-ALK (Figure 3K-L). Altogether, we identified 
a cryptic insertion of the 5’TPM3 into the rearranged ALK locus, loss of the 5’ALK and 3’TPM3 
sequences, and gain of two copies of TPM3-ALK in tetraploid neoplastic cells. 
 
Functional studies  
Gain of the EEF1G-, RFN213-, ATIC- and TPM3-ALK hybrid genes found in the present cases 
contrasts with a constant occurrence of a single copy of NPM1-ALK in t(2;5)-positive ALCL.20-22 We 
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hypothesized that ALCLs harboring the variant rearrangements compensate an insufficient expression 
of the ALK fusions (driven by relatively weak promoters of the partner genes) by an increased dosage 
of the chimeric gene. To validate this concept, we analyzed expression levels of NPM1, EEF1G, 
RNF213, ATIC and TPM3 in various normal lymphoid cells and T-cell malignancies using previously 
generated RNAseq data.23,24 The analysis revealed a significantly lower (p-value <0.001) expression 
of RNF213, ATIC and TPM3 in all samples when compared to NPM1 (Figure 4A). In contrast, 
expression of EEF1G was similar to that of NPM1. Based on these findings, we hypothesized that 
oncogenic transforming properties of the three variant ALK fusions, RFN213-ALK, ATIC-ALK and 
TPM3-ALK, could be lower than the strong NPM1-ALK kinase. To validate our hypothesis, we 
attempted to generate the Npm-Alk and Atic-Alk fusions in the genome of Ba/F3 cells using 
CRISPR/Cas9 genome editing. The expression level of Npm1 is around 50-fold higher than the 
expression level of Atic in this cell line, making it a suitable model to test our hypothesis (Figure 4B). 
We designed a gRNA targeting exon 20 of Alk and gRNAs targeting Npm1 and Atic in regions 
corresponding to the breakpoints observed in our patient samples (Figure 4C). gRNAs targeting Alk 
and a fusion partner were simultaneously introduced in Ba/F3 Cas9 cells by electroporation. Upon IL3 
depletion, both endogenous Alk fusions were able to transform the Ba/F3 Cas9 cells, although cells 
harboring an endogenous Atic-Alk fusion needed more time to recover from the IL3 depletion (Figure 
4D). In addition to the slower transformation rate, cells harboring an endogenous Atic-Alk fusion 
presented with a lower growth rate after transformation than cells with an endogenous Npm1-Alk 
fusion (Figure 4E). FISH demonstrated the presence of one copy of the Npm1-Alk and Atic-Alk 
chimeric genes per cell in the respective cell lines (Figure 4F-G). After keeping the cells in culture for 
three months, we observed gain of 1-3 copies of the Atic-Alk fusion gene in approximately 20% of the 
cells. In contrast, the Npm1-Alk cell line kept a single copy of the chimeric gene in all cells (Figure 4H). 
Altogether, these data demonstrate that the Npm1-Alk fusion is a more potent driver of proliferation 
than Atic-Alk in Ba/F3 cells, and that the expression level of the fusion partner is a key factor in the 
transformation potential of the oncogenic fusions.  
 
Discussion 
Our study provided evidence that ALCL driven by at least three variant ALK fusions, RNF213-ALK, 
ATIC-ALK and TPM3-ALK, is characterized by a copy number gain of the ALK hybrid gene. Gain of 
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RNF213-ALK was already observed by us in the previously reported case of ALK+ ALCL, harboring 
two copies of der(17)t(2;17)(p23.2;q25.3)/RNF213(ALO17)-ALK.17 Genetic mechanisms underlying 
amplification of RNF213-ALK in case 2, however, remain unknown. Notably, the four ATIC-ALK-
positive cases presented here, as well as all reported ATIC-ALK cases documented by FISH,19,25-27 
showed extra copies of the chimeric gene. We previously documented that the ATIC-ALK fusion is 
generated by a pericentric inv(2)(p23q35) and is constantly accompanied by isochromosome 2q 
(derivative of inv(2)) comprising two extra copies of ATIC-ALK.19,25 Based on these data, we presume 
that the reported cases here also carry inv(2)(p23q35) and 1-3 copies of ider(2q). Intriguingly, a similar 
mechanism of gain of ALK hybrid emerged to underpin the TPM3-ALK rearrangement detected in 
case 7. The fusion was likely created by insertion of 3’ALK/2p23p25 at 1q21.3/TPM3 and gained by a 
subsequent formation of ider(1)(q10). In the second TPM3-ALK-positive case, however, the chimeric 
gene was produced by a cryptic insertion of the 5’TPM3 into the rearranged ALK locus and gained by 
a duplication of the der(2), like in the case reported by Siebert et al.28 Notably, one more informative 
case with TPM3-ALK also presented with 2-3 copies of the 3’ALK.29 Lamant et al.6, who originally 
described the TPM3-ALK fusion in ALK+ ALCL, linked it to t(1;2)(q25;p23). Considering, however, an 
opposite transcriptional orientation of both genes, generation of the in-frame TPM3-ALK fusion 
requires more complicated events, as illustrated in the present and previously reported cases.28  
Altogether, our genetic findings supported by the published data,17,19,26-29 highlight a strong 
association of RNF213-ALK, ATIC-ALK and TPM3-ALK with a copy number gain of the chimeric gene. 
A spectrum of such ALK fusions is probably broader, but a frequent lack of cytogenetic and/or FISH 
data hampers their identification. These observations contrast with ALCL driven by NPM1-ALK20-22 and 
at least three variant fusions, CLTC-ALK17, TPM4-ALK30,31 and TRAF1-ALK27,32, shown to carry a 
single copy of the ALK hybrid gene. We initially included to the former category also the novel EEF1G-
ALK variant found to be duplicated on der(11). Given, however, that two recently published ALCL 
cases with EEF1G-ALK did not show copy number gain of the ALK fusion gene,33 duplication of 
EEF1G-ALK in our case was likely associated with progression of the disease, similar to a case of 
leukemic ALK+ ALCL with extra copy of NPM1-ALK.34 This conclusion is additionally supported by our 
other data illustrating a strong expression of EEF1G in normal and malignant T cells, similar to that of 
NPM1. Thus, there is no reason why the EEF1G-ALK fusion gene would require an increased copy 
number.   
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In contrast, expression of RNF213, ATIC and TPM3 in lymphoid cells was significantly lower than 
NPM1 and EEF1G. These findings support the concept that ALCL driven by the RNF213-ALK, ATIC-
ALK and TPM3-ALK fusions might require an increased dosage of ALK chimeric gene to compensate 
an insufficient expression of ALK in neoplastic cells. To test if the best documented Atic-Alk fusion is 
indeed less transforming than the Npm1-Alk fusion, we generated the Npm1-Alk and Atic-Alk fusion 
genes by inducing Cas9 mediated chromosomal rearrangements in Ba/F3 cells. Growth properties of 
these engineered cells showed that the transformation potential of Atic-Alk is significantly lower when 
compared to Npm1-Alk, likely due to a lower expression level of Atic. Interestingly, the tendency of the 
Atic-Alk-positive Ba/F3 cells to gain extra copies of the Atic-Alk chimeric gene recapitulates the events 
observed in the original tumors and confirms the selective pressure of the cells to acquire additional 
copies of the Atic-Alk fusion. We also attempted to generate an endogenous Rnf213-Alk fusion, but 
since Rnf213 is very lowly expressed in Ba/F3 cells, this fusion could not transform the cells. Tpm3 
was not included in the functional studies, since it was only recently added to the study. Of note, 
Giuriato et al.35 previously showed that in conditional knock-in mice both TPM3-ALK and NPM1-ALK 
could induce B-cell lymphoma/leukemia with a similar disease latency. In these transgenic mice, 
however, the expression levels of both ALK fusions were similar, since their expression was driven by 
an external promoter. This could explain the observed equal tumorigenic potential of both ALK fusions.  
 
The novel EEF1G-ALK fusion identified by us in a child with ALK+ ALCL extends the already long 
list of ALK fusion partners comprising approximately 20 genes.7 The very recent report of two pediatric 
patients with EEF1G-ALK33 indicates that the fusion is recurrent and strongly associated with pediatric 
ALK+ ALCL. EEF1G, located at 11q12.3, has 10 exons encoding for an eukaryotic translation 
elongation factor 1 gamma. Together with α, β and δ subunits, it forms the eukaryotic elongation factor 
complex, which is predominantly involved in protein biosynthesis with an elongation of the polypeptide 
chains.36,37 EEF1G comprises a glutathione transferase (GST)-like N-terminus domain and a C-
terminus (CT) domain.37 Although all four subunits of the elongation factor complex are highly 
expressed in most eukaryotic cells, the role of human EEF1G is poorly understood. Notably, an 
increased expression of EEF1G has been detected in various human carcinomas.37-40 It has been 
suggested that overexpression of EEF1G stimulates the overgrowth of neoplastic cells.41 In the 
present case of ALK+ ALCL, exons 1 to 8 of EEF1G are fused to exon 20-29 of ALK, resulting in a 
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chimeric protein with the complete GST-like-N-terminal domain and part of the CT domain of EEF1G, 
fused to the complete intracellular protein tyrosine kinase (PTK) domain of ALK (Figure 2B). Even 
though the complete PTK domain is involved, the ALK fragment contains the final 513 amino acids, 
which is shorter in comparison to the fragment involved in most other ALK-fusions, containing the final 
563 amino acids.42 Of note, both cases reported by Palacios et al.33, revealed breakpoints within intron 
7 of EEF1G and intron 20 of ALK. As the fusions were identified by RNAseq, genetic mechanisms 
underlying these rearrangements are unknown. The postulated t(2;11)(p23;q12.3), however, is 
unlikely, because of an opposite transcriptional orientation of both genes, similar to TPM3 and ALK 
(www.ensembl.org). Functional studies performed by the authors provided evidence of the 
dimerization properties of the EEF1G-ALK fusion, constitutive activation of ALK kinase and its strong 
oncogenic potential similar to that of NMP1-ALK.  
Our patient with EEF1G-ALK experienced an unfavorable and fatal clinical course. Although ALK+ 
ALCL has a relatively good prognosis, chemoresistant and aggressive forms of this lymphoma, 
recurrently featured by MYC aberrations, have been recurrently reported.32,43-45 Notably, our case 
displayed a microdeletion neighboring MYC and loss of CDKN2A/B at 9p21, a known poor prognostic 
factor in tumor.46 We presume that a focal del(8)(q24q24) could activate MYC by e.g., loss of negative 
regulatory elements upstream of the gene. Although clinical data of the EEF1G-ALK-positive cases 
reported by Palacios et al.33, are not available, we believe that an aggressive clinical course and 
unfavorable prognosis of certain ALK+ ALCL is not determined by the type of ALK fusion, but rather by 
secondary hits affecting potent oncogenes and tumor suppressor genes (e.g. MYC, TP53, PRDM1 
and CDKNA2/B).32,44,45,47  
In summary, we investigated eight recently diagnosed cases of ALK+ ALCL with a cytoplasmic-only 
expression of ALK and identified one novel EEF1G-ALK rearrangement and three already known 
fusions, RNF213-ALK, TPM3-ALK and ATIC-ALK. Occurrence of the latter rearrangement in four out 
of eight (50%) studied cases confirms that ATIC-ALK is the most prevalent variant fusion in ALK+ 
ALCL. Importantly, RNF213-ALK, TPM3-ALK and ATIC-ALK fusions were recurrently present in two or 
more copies, contrasting with the NPM1-ALK chimeric gene, constantly occurring in one copy. Our 
functional studies show that ALK+ ALCL driven by ATIC-ALK compensates the weak expression and 
possibly weak oncogenic properties of this variant ALK fusion by an increased gene dosage. We 
propose a similar explanation for the copy number gain of RNF213-ALK and TPM3-ALK. Altogether, 
14 
 
our findings support the hypothesis that the transforming capacities of ALK fusions depend on the 
biological features of the partner genes.48  
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Table 1. Relevant clinical and pathological data. 
Case Sex/Age 
at 
diagnosis 
Sites of 
involvement, 
Ann Arbor stage 
Immunophenotype 
Histology 
Treatment Outcome Survival 
(months) 
Status (A/D) 
1 M/5 skin, supra and 
infradiaphragmat
ic lymph nodes. 
Stage IV. 
CD3-, CD20-, CD30+, CD4 partial, 
CD8-, ALK(cyto)+ , TIA1+, 
perforin +, granzyme B focal + 
lymphohistiocytic subtype sequential polychemotherapy (ALCL 
99 protocol, high risk);1st R: ALCL 
relapse protocol, BEAM + auto  SCT; 
2nd R: weekly vinblastine until 1,5 
year; 3rd R: daily crizotinib + weekly 
vinblastine followed by MUD allo 
SCT 
1st R 8 mo AD; 2nd 
R: 15 mo AD; 3rd 
R: 61 mo AD 
72 D in CR (toxic 
death: severe 
GVHD, 
respiratory 
failure) 
2 M/55 lymph nodes 
(neck). Stage III. 
CD3-, CD20-, CD30+, CD5-, CD10-
, prekeratin-, EMA-, CD2-, CD4+, 
CD7-, CD8-, TIA1-, granzymB-, 
perforin+, ALK(cyto)+, EBV-, bcl2 
weak+, CD43- 
classical morphology of 
ALCL  
 
8 CHOP; 1
st
 R: 4  DHAP; BEAM +  
auto SCT   
CR after CHOP; R: 
CR after DHAP 
63 A 
3 F/49  lymph nodes 
(axillary). Stage I.  
CD2-, CD3-, CD20-, PAX5-, CD15-, 
CD30+, CD4+, CD8-, CD5-, 
MUM1+, ALK(cyto)+, TIA1-, 
granzymeB-, perforin+, EBV-, 
EMA+ 
intrasinusoidal growth, 
numerous plasma cells and 
eosinophils in the 
background 
N CHOP CR 20  A 
4 M/77 lymph nodes 
(neck). Stage I.   
CD2-, CD30+, CD4-, CD8-, 
ALK(cyto)+,TIA1-, granzymeB-, 
perforin+, EMA+, weak CD138, 
PAX5-, IgA-, HHV8-, CD7-, CD45-, 
CD79a- 
classical morphology of 
ALCL, foci of necrosis; 
histiocytes in background 
 
6 CHOP CR 24  A 
5 M/52 lymph nodes 
(mesenteric). 
Stage IIA. 
CD30+, CD4+, CD8-, ALK(cyto)+, 
TIA1+, perforin+, granzymeB+, 
EBV-,EMA+ 
large multinuclear cells 
with nucleoli; polymorphic 
stromal reactions with 
numerous plasma cells, 
neutrophils and eosinophils 
8 CHOP CR 45  A 
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6 F/78 Bone, supra and 
infra 
diaphragmatic 
lymph nodes 
Stage IVB 
CD30+, ALK (cyto) +, CD45+, 
CD4+, CD20 weak+, Pax5 weak+, 
CD3-, CD5-, CD2-, CD8- 
Perforin+, granzyme+, EMA+, 
TIA1- 
classical morphology of 
ALCL 
8 CHOP CR 14 A 
7 M/65 lymph nodes 
(neck, axillary, 
retoroperitoneal, 
iliacal). Stage IIIa. 
  
CD30+, CD15 false +, CD20-, 
CD3-, misdiagnosed as classical 
Hodgkin. 
Performed in 2016 after 
recurrence: PAX5-, CD2-, CD4-, 
CD8-, ALK(cyto)+, TIA1+ (partial), 
perforin+, granzymeB+ (partial), 
EBV- 
Nodular sheet-like 
proliferation of 
immunoblastic to 
anaplastic cells; prominent 
intrasinusoidal localization; 
similar at recurrence, plus 
prominent histiocytic 
response with 
erythrophagocytosis and 
emperipolesis 
2002: (initially misdiagnosed as 
classical Hodgkin): 6 ABVD + RT at 
left cervical and axillar region (30 
Gy). 
 
Relapse in February 2016: stadium 
IVB (neck, supra- and 
infradiaphragmatic lymph nodes, 
lung (subpleural lesions)). 8 CHOP (3 
received).  
R: 168 mo AD 
 
166 D 
8 F/13 lymph nodes 
(infradiaphragma
tic : 
retroperitoneal, 
iliacal) Stage IIA 
CD30+, ALK (cytoplasmic, 
membraneous)+, EMA+, TIA1+, 
perforin+, GranzymeB+, CD4+ 
(weak), CD20-, CD3- 
Diffuse parenchymal and 
pseudo-cohesive 
intrasinusoidal spread of 
characteristic Hallmark 
cells. No prominent stromal 
reaction. 
ALCL 99 protocol: 6 courses of 
polychemotherapy 
CR 14  A 
abbreviations: M, male; F, female; R, relapse;  SCT, stem cell transplantation; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; CHOP, cyclophosphamide-
adriamycin-vincristine-prednisone; DHAP, dexamethasone-cytarabine-cisplatin; BEAM, carmustine-etoposide-cytarabine- melphalan; MUD, matched 
unrelated; RT, radiotherapy; N, number of cycles unknown; CR, complete response; AD , after diagnosis; D, died; A, alive; GVHD, graft versus host disease 
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Table 2. Results of cytogenetic and molecular studies 
Case Sample/
status 
Cytogenetics aCGH profile FISH ALK fusion 
LSI ALK Other probes partner gene 
(localization) 
detected by 
1
a
 LN/P 44-47,XY,-Y,del(2)(p23),-5[3], 
der(6)t(5;6)(q22;p25),add(8)(p23)[3],-9, 
del(10)(q25),der(11)(?::11pter->q12.3::2p23-> 
2pter::2pter->p23::11q12.3->q11::q13.5-> 
23.1::?),add(12)(q24)[3],+16[2],+1-4mar[4] 
gains: 1q21.3q44, 2p23.2p25.3, 
5q15q35.3, 6p22.2p25, 
11q11q13.4, 20q13.1q13.33, 
22q13.1q13.33 
losses: 8q24q24,9p21.3p24.3, 
10q25.3q25, 11q22.3q25 
ish: 2p(F),der(2)(G), 
der(11)( Rx2);  
nuc ish:1F,1G,2R (85%) 
WCP2:2+,del(2p)+,de
r(11)+; 
WCP11:11+,der11+; 
5’EEF1G-SO/3’ALK-
SG:2F1R1G; LSI MYC: 
8F,8GRdim 
EEF1G (11q12.3) 5'RACE PCR  
2
a
 LN/D NM gains: 1q21.3q44, 2p23.2p25.3, 
4p12p16, 5q33.3q35.3, 6, 
12q15q23.2, 16p11.2p13.3, 
17q23.3q25.3, 21q11.2q22.3 
losses: 1p36.2p36.3, 5q15q21.2, 
18q11.2q23 
nuc ish:1-3F,1-3G,1-7R 
(19%) 
RFN213 BA:3F3-7R3-
7G; 
5’RFN213-SO/3’ALK-
SG:3-7F2-3R2-3G; 
RNF212 BA:5-7G 
ITK BA: 5-7R 
5’RNF SO/3’ITK-SG: 
5-7R5-7G 
RFN213 (17q25.3) LCFGS 
3
b
 LN/D ND ND nuc ish:1-2F,1-2G,5-7R 
(16%) 
ATIC BA: variable 
pattern with gain of 
red signals; 5'ATIC-
SO/3'ALK- SG: 2-5F 
and variable R/G 
signals 
ATIC (2q35) FISH 
4
b
 LN/D ND ND nuc ish: 1F,1G,5R (15%) ATIC BA: variable 
pattern with gain of 
red signals; 5'ATIC-
SO/3'ALK- SG: 2-5F 
and variable R/G 
signals 
ATIC (2q35) FISH 
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5
b
 LN/D ND ND nuc ish:1-3F,1-2G,3-5R 
(21%) 
ATIC BA: variable 
pattern with gain of 
red signals; 5'ATIC-
SO/3'ALK- SG: 2-5F 
and variable R/G 
signals 
ATIC (2q35) FISH 
6
a
 LN/D NM ND nuc ish:1-2F,1-3G,3-5R 
(9%) 
ATIC BA: variable 
pattern with gain of 
red signals; 5'ATIC-
SO/3'ALK- SG: 2-5F 
and variable R/G 
signals 
ATIC (2q35) FISH 
7
a
 LN/D 88-89,XXY,-
Y,i(1)(q10),+i(1)(q10),del(2)(p11),+del(2)(p11),+
del(2)(p23)x2,-4,-5,-8,-8,-11,-15,-15,-18,-
18,+20[2],+20[2],-21,-22[2],+2-6mar[cp3] 
ND nuc ish:2-5F,1-2G, 5-6R 
(15%) 
TPM3 BA: 1-
2F5(RsepG); 
5'TPM3-S0/3'ALK-SG: 
1-2R1-3G5F 
TPM3 (1q21.3) FISH 
LN/P 47,XY,ins(1;2)(q21.3;p23p25),+ider(1)(q10)ins(1
;2)(q21.3;p23p25),del(2)(p23)[2] 
ND nuc ish:1F,1G,3R (24%) TPM3 BA: 
1F3(RsepG);         
5'TPM3-S0/3'ALK-SG: 
1R1G3F 
 
 
 
8 LN/D 88,XX,-X,-X,-1,add(1)(q44),+2,-
3,add(4)(p16),+5,+7,-11,+12,-13,-15,-
16,+i(17)(q10),-19,-20[1] 
ND 2F,4xdel(2)(p23p?)R 
Nuc ish:1F4R (11%) 
TPM3 BA: 2F4R; 
5'TPM3-S0/3'ALK-
SG:2R1G4F 
TPM3 (1q21.3) TLA 
abbreviations: LN, lymph node; D, diagnosis; P, progression; NM, no mitosis, ND, not done; ish, in situ hybridization; nuc ish, interphase in situ hybridization; 
F, fused ; G, green, R, red; BA, break apart; RACE PCR, rapid amplification of cDNA ends; LCFGS, low coverage full genome sequencing; TLA, Targeted Locus 
Amplification technology (http://www.cergentis.com/tla-technology) 
a, FISH performed on cytogenetic specimen; b, FISH performed on FFPE material 
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Legend to the figures 
 
Figure 1. Cytogenetic and molecular analysis of case 1. (A) Examples of FISH experiments with LSI 
ALK and LSI MYC break apart probes. Metaphase FISH demonstrated break apart LSI ALK pattern 
associated with a duplication of the red/3’ALK signal on der(11) (left image). Paints for chromosomes 
2 (red) and 11 (green) confirmed insertion of 2p23p25 at 11q12 (inset). The same aberrant LSI ALK 
pattern (one colocalized-one green-two red signals) was  observed in interphase cells (middle image). 
Metaphase FISH with LSI MYC showed a diminished red signal on der(8), confirming a focal deletion 
at 8q24.21 (right image). (B) Schematic representation of the EEF1G, ALK and EEF1G-ALK protein 
structures (upper panel). Sequencing of the fragment amplified by EEF1G-ALK nested RT-PCR 
identified an in-frame fusion between exon 8 of EEF1G (breakpoint between exon 8 and 9) and exon 
20 of ALK (breakpoint in the middle of exon 20) as shown in the electropherogram (lower panel). (C) 
Array CGH profile of case 1 showing several unbalanced regions, including gain of 2p23pter and 
11q11q13.4 (marked). (D) The selected 2pter (upper panel) and 11q (lower panel) regions. Note the 
2p23pter gain-associated break within the ALK gene (gain of 3’ALK) and localization of EEF1G in the 
middle of gained 11q11q13.4 region. 
 
Figure 2. Cytogenetic and molecular analysis of case 2. (A) Examples of interphase FISH 
experiments. Note a break apart pattern of LSI ALK and RNF213 BA probes associated with gain of 
six 3’ALK (red) signals  (left image) and six 5’RNF213 (red ) signals (middle image). Several 
colocalized  5’RNF213 (red) and the 3’ALK (green) signals in interphase cells confirm presence and 
gain of the RNF213-ALK hybrid gene in this case (left image). (B) Schematic representation of the 
RNF213, ALK and RNF213-ALK protein structures (upper panel). Low coverage full genome 
sequencing resulted in at least eight single read pairs covering the in-frame fusion between exon 8 of 
RNF213 and exon 20 of ALK (lower panel). (C) Array CGH profile of case 2 showing several 
unbalanced regions, including gains of 2p23pter and 17q23qter (marked). (D) The selected 2p23pter 
(upper panel) and 17q23qter (lower panel) regions evidencing the gain-associated breaks within the 
ALK and RNF213 genes, respectively. 
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Figure 3. Cytogenetic and FISH analysis of cases 3, 7 and 8. (A-C) Note a break apart pattern of LSI 
ALK and ATIC BA probes associated with a gain of four 3’ALK (red) and four 5’ATIC (red) signals, 
respectively, in case 3. Several colocalized 5’ATIC/3’ALK signals in interphase cells demonstrate gain 
of the ATIC-ALK hybrid gene in this sample. Similar FISH results were obtained in cases 4 and 5. 
Case 7: (D) Partial karyotype (at time of relapse) illustrating insertion of 2p23p25 at 1q21.3 
(arrowhead), isochomosome 1q containing duplicated long arm of ins(1;2)(q21.3;p23q25) (two 
arrowheads) and del(2)(p23) (arrow). (E) Note rearrangement of ALK and gain of two extra 3’ALK 
(red) signals, and (F) three separated red and green TPM3 BA probes, likely marking ins(1) and 
ider(1). (G-I) Similar FISH patterns were observed in the diagnostic sample. Case 8: (J) Note four 
copies of der(2) marked by red signals of LSI ALK, (K) unbalanced rearrangement of TPM3 and (L) 
loss of TPM3 from one chromosome 1 and four copies of der(2)/TPM3-ALK.  
 
Figure 4. Functional analysis of the NPM1-, EEF1G-, RNF213-, TPM3- and ATIC-ALK fusions. (A) 
Expression analysis of the five ALK partner genes using previously generated RNA-sequencing 
data23,24 In contrast to EEF1G, expression of TPM3, RNF213, and ATIC is significantly lower (p-value 
<0,001) when compared to NPM1 in different malignant and non-malignant cell types (HSTL = 
hepatosplenic T-cell lymphoma (n=4), T-ALL = T-cell acute lymphoblastic leukemia (n=5), PTCL = 
peripheral T-cell lymphoma (n=2), Spleen (n=1), Thymus (n=1), LN = lymph nodes (n=3), Th1 (n=5), 
Th2 (n=5), Treg (n=5), and CD4 naïve T-cells (n=4)). Error bars represent the standard deviation 
(SD). (B) QRT-PCR on Ba/F3 Cas9 cells showing the expression levels of Npm1 and Atic. The 
expression of Atic is significantly lower than Npm1 (p<0,001). Error bars represent the SD. (C) 
Representation of the Alk, Npm1, and Atic mouse genes. Exons are indicated by vertical bars. Red 
arrows indicate the location of the gRNA target sites. (D) Growth curve showing the transforming 
capacities of Ba/F3 Cas9 cells harboring an endogenous Npm1-Alk or Atic-Alk fusion. Error bars 
represent the SD. (E) Growth curve showing the growth rate of Ba/F3 Cas9 cells after transformation 
by the endogenous Alk fusion. Error bars represent the SD. (F-H) Examples of metaphase and 
interphase FISH results showing the endogenous Alk fusions in Ba/F3 Cas9 cells. Arrows point 
colocalized signals/chimeric genes. Note a constant presence of a single copy of Npm1-Alk and gain 
of Atic-Alk in late cultures.  
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Supplemental information 
 
Supplemental Methods  
 
5’ Rapid Amplification of cDNA Ends Polymerase-Chain-Reaction (RACE-PCR)  
 Total RNA was extracted from 20µm sections of frozen tissue samples using TRIzol Reagent (Life 
Technologies, Merelbeke, Belgium). With random primers and Superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA), one microgram of total RNA was reverse transcribed into cDNA using 
random hexamers and SuperScript III (Life Technologies, Merelbeke, Belgium). 
5’RACE-PCR experiments were performed following a previously described protocol.1 The used 5’ 
RACE PCR primers are listed in the Supplemental Table 2. The final PCR products were cloned in into 
the pJET1.2 CloneJET vector (Thermo Fisher Scientific (Fermentas), Waltham, MA). Subsequently, 
Sanger sequencing of the PCR products was performed and Sanger chromatograms were analyzed 
using CLC Main Workbench 6 (CLC Bio Inc., Cambridge, MA). 
 
Low coverage full genome sequencing (LCFGS)   
The Illumina standard kit (Illumina® TruSeq™ DNA Sample Preparation Kit) was used for the DNA-
sequencing sample preparation according to the manufacturer’s protocol (Illumina, San Diego, CA). 
The quality of the libraries was checked by Agilent Technologies 2100 Bioanalyzer with the Agilent DNA 
1000 Kit (Agilent, Santa Clara, CA). Prepared libraries were sequenced using HiSeq 2000 (Illumina) 
operated in paired-end 2×100 bp mode. Reads were quality-filtered using standard Illumina process. 
To analyze the data, the fastq files were mapped to the reference human genome (Human.B37.3) using 
the Ensembl gene model (Homo_sapiens.GRCh37.67). The mapping and downstream analysis were 
performed with the software ArrayStudio, version 6.2 (www.omicsoft.com).  
 
Targeted Locus Amplification  
Viably frozen lymphoma cells were sent to Cergentis B.V. (Utrecht, the Netherlands) for Targeted 
Locus Amplification (TLA) and sequencing. Sample preparation, sequencing and data analysis were 
performed as previously described.2 
 
Nested Reverse-Transcription Polymerase-Chain-Reaction (RT-PCR)  
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Fusion ALK transcripts were validated by nested RT-PCR. First strand cDNA was prepared as 
described above and RT-PCR was done on a cDNA template using two rounds of conventional PCR 
following standard protocols that come with Taq DNA polymerase (Roche Diagnostics GmbH, 
Mannheim, Germany). The primers were designed to amplify 400-600 bp fragments containing the 
identified fusion boundary. Subsequently, Sanger sequencing of the PCR products was performed and 
Sanger chromatograms were analyzed using CLC Main Workbench 6 (CLC Bio Inc.). The primers used 
can be found in the Supplemental Table 2. 
 
Supplemental Tables 
Supplemental Table 1. List of FISH probes. 
Supplemental Table 2. List of primers. 
Supplemental Table 3. The guide RNA sequences. 
 
Supplemental Figures 
 
Supplemental Figure 1. Generation of Ba/F3 Cas9 expressing cells.  
 
Supplemental Figure 2. Map of the plasmid  pX321. 
 
Supplemental Figure 3. Morphology and immunophenotype.  Representative histopathology of case 1 
with the novel EEF1G-ALK fusion and case 4 with the ATIC-ALK fusion. Hematoxylin and eosin staining 
shows an anaplastic lymphoid cell proliferation with characteristic hallmark and doughnut cells (top 
insets). The neoplastic cells overexpress CD30 and cytoplasmic ALK1.   
 
Supplemental Figure 4. Results of the TLA/sequencing performed in case 8. (A) The primer sets were 
used in individual TLA amplifications. PCR products were purified and library prepped using the Illumina 
NexteraXT protocol and sequenced on an Illumina Miniseq sequencer. Reads were mapped using 
BWA-SW, which is a Smith-Waterman alignment tool. This allows partial mapping which is optimally 
suited for identifying break spanning reads. The human genome version hg19 was used for mapping. 
(B) TLA sequence coverage across the human genome. Data shown was generated using primer set 
1 (upper panel) and set 2 (lower panel). The different chromosomes are indicated on the y-axis, the 
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chromosomal position on the x-axis. Encircled in blue is the position of the primer-set at ALK gene 
locus, in red is the fusion partner. A high coverage peak in chromosome 2 was identified at the ALK 
locus. An additional peak at chromosome 1 at the TPM3 gene was identified. (C) IGV screenshot 
showing the sequence coverage across the ALK gene human locus. Coverage generated across 
chr2:29,446,372-29,447,630 using primer set 1 (top panel) and set 2 (bottom panel) are depicted. Blue 
arrow indicates the breakpoint position. Green arrows indicate primer position. Y-axis is limited to 100x. 
(D) IGV screenshot showing the sequence coverage across the breakpoint at the TPM3 gene human 
locus. Coverage generated across chr1:154,121,228-154,168,475 using primer set 1 (top panel) and 
primer set 2 (bottom panel) are depicted. Blue arrow indicates the breakpoint. Y-axis is limited to 100x. 
(E) Results of sequencing. 
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